Celldex Therapeutics, Inc. (CLDX) Gross margin 2016–2025
Celldex Therapeutics, Inc. (CLDX) gross margin by fiscal year — reported gross profit divided by reported revenue.
87.1%FY2025 · since FY2016: 76.4% → 87.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 87.1% | -10.1 pp |
| FY2024 | 97.2% | +1.5 pp |
| FY2023 | 95.6% | -0.1 pp |
| FY2022 | 95.8% | -2.1 pp |
| FY2021 | 97.8% | +0.5 pp |
| FY2020 | 97.3% | +0.1 pp |
| FY2019 | 97.2% | +4.5 pp |
| FY2018 | 92.7% | -1.8 pp |
| FY2017 | 94.5% | +18.1 pp |
| FY2016 | 76.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice